Comparing Inflarx (IFRX) & Dermira (DERM)

Dermira (NASDAQ:DERM) and Inflarx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Dermira has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Inflarx has a beta of -0.69, indicating that its stock price is 169% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dermira and Inflarx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermira 0 2 5 0 2.71
Inflarx 0 0 6 0 3.00

Dermira presently has a consensus price target of $16.29, indicating a potential upside of 161.82%. Inflarx has a consensus price target of $45.50, indicating a potential upside of 26.00%. Given Dermira’s higher probable upside, equities analysts plainly believe Dermira is more favorable than Inflarx.

Profitability

This table compares Dermira and Inflarx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dermira -496.49% -184.43% -41.67%
Inflarx N/A N/A N/A

Insider & Institutional Ownership

84.9% of Dermira shares are held by institutional investors. Comparatively, 57.1% of Inflarx shares are held by institutional investors. 14.8% of Dermira shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Dermira and Inflarx’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dermira $4.54 million 57.71 -$303.26 million ($4.39) -1.42
Inflarx N/A N/A -$27.39 million ($2.94) -12.28

Inflarx has lower revenue, but higher earnings than Dermira. Inflarx is trading at a lower price-to-earnings ratio than Dermira, indicating that it is currently the more affordable of the two stocks.

Summary

Inflarx beats Dermira on 7 of the 13 factors compared between the two stocks.

Dermira Company Profile

Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company’s product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings for Dermira Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dermira and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *